← Leaderboards
Kyle H Rohde
University Of Central Florida
$4,255,870
Attributed
$7,395,873
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,395,873 · 11
By mechanism
R21$3,332,009 · 8
R01$2,725,964 · 2
R33$1,337,900 · 1
Top collaborators
- Yulia Gerasimova6 shared
- Pedro Eduardo Almeida Silva4 shared
- John D Buynak3 shared
- Konstantin V Korotkov3 shared
- Robert Henry Cichewicz2 shared
- Robert William Huigens2 shared
- Fenfei Leng2 shared
- Adel Nefzi2 shared
Most similar at University Of Central Florida
Same institution · by research overlap
- Yulia Gerasimova$387,106
- Pedro Eduardo Almeida Silva$195,559
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsMycobacterium TuberculosisIn VitroBacteriaPharmaceutical PreparationsTuberculosisGenus MycobacteriumIn VivoTreatment ProtocolsPathogenRegimenEvaluationSpecificityInfectionPublic HealthCellsLeadLibrariesResistanceTuberculosis DrugsPhenotypeTuberculosis TreatmentDrug ResistanceNon-Tuberculosis Mycobacteria
Grant awards (26)
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$681,269
R01 · FY2025 · AI
Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.$187,091
R21 · FY2025 · AI · contact PI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$698,616
R01 · FY2024 · AI
Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.$237,288
R21 · FY2024 · AI · contact PI
Novel gyrase inhibitors targeting Mycobacterium tuberculosis$186,265
R21 · FY2024 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics$759,402
R01 · FY2023 · AI
Novel gyrase inhibitors targeting Mycobacterium tuberculosis$235,375
R21 · FY2023 · AI
Point-of-care detection of TB and NTM pathogens with Fluorescent Deoxyribozyme Sensors and 3D-printed, battery powered device.$147,383
R01 · FY2023 · AI · contact PI
Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics$190,125
R21 · FY2022 · AI · contact PI
CRISPRi-based discovery and in vivo validation of drug targets in M. abscessus$190,000
R21 · FY2022 · AI · contact PI
Point-of-care detection of TB and NTM pathogens with Fluorescent Deoxyribozyme Sensors and 3D-printed, battery powered device.$147,383
R01 · FY2022 · AI · contact PI
Optimization and mechanistic studies of halogenated phenazines and quinolines as anti-tuberculosis therapeutics$241,150
R21 · FY2021 · AI · contact PI
CRISPRi-based discovery and in vivo validation of drug targets in M. abscessus$228,000
R21 · FY2021 · AI · contact PI
Point-of-care detection of TB and NTM pathogens with Fluorescent Deoxyribozyme Sensors and 3D-printed, battery powered device.$146,590
R01 · FY2021 · AI · contact PI
Point-of-care detection of TB and NTM pathogens with Fluorescent Deoxyribozyme Sensors and 3D-printed, battery powered device.$145,321
R01 · FY2020 · AI · contact PI
Synthesis of natural product scaffold selectively active against dormant Mycobacterium tuberculosis$186,625
R21 · FY2019 · AI
Synthesis of natural product scaffold selectively active against dormant Mycobacterium tuberculosis$236,325
R21 · FY2018 · AI
Exploiting Fungal Natural Products to Discover Novel Scaffolds That Inhibit Dormant and Drug-Resistant TB$186,189
R21 · FY2018 · AI · contact PI
Development of a method for visual detection of Mycobacterium tuberculosis complex$177,776
R21 · FY2018 · AI
Discovery of marine natural products targeting latent M. tuberculosis$442,200
R33 · FY2017 · AI · contact PI
Exploiting Fungal Natural Products to Discover Novel Scaffolds That Inhibit Dormant and Drug-Resistant TB$235,314
R21 · FY2017 · AI · contact PI
Development of a method for visual detection of Mycobacterium tuberculosis complex$205,317
R21 · FY2017 · AI
Discovery of marine natural products targeting latent M. tuberculosis$443,250
R33 · FY2016 · AI · contact PI
Discovery of marine natural products targeting latent M. tuberculosis$452,450
R33 · FY2015 · AI · contact PI
Discovery of marine natural products targeting latent M. tuberculosis$180,569
R21 · FY2014 · AI · contact PI
Discovery of marine natural products targeting latent M. tuberculosis$228,600
R21 · FY2013 · AI · contact PI